A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma

ABSTRACT Background Selinexor (SEL) is a nuclear exportin 1 inhibitor that blocks the transport of nuclear proteins, including tumor suppressors, to the cytoplasm. Preclinical data suggest that the combination of SEL with checkpoint blockade may result in improved response to immunotherapy. Methods...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Omar Alhalabi, Mohamed A. Gouda, Denái R. Milton, Hassan Ahmed Momin, Bulent Yilmaz, Bettzy Stephen, Chinenye Lynette Ejezie, Justin Tyler Moyers, Serdar A. Gurses, Jeffrey How, Siqing Fu, Jordi Rodon, David S. Hong, Sarina A. Piha‐Paul, Vivek Subbiah, Ecaterina Elena Dumbrava, Daniel D. Karp, Filip Janku, Funda Meric‐Bernstam, Nizar M. Tannir, Aung Naing
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2025-02-01
Sarja:	Cancer Medicine
Aiheet:	immunotherapy renal cell carcinoma selinexor
Linkit:	https://doi.org/10.1002/cam4.70280
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!